Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Edralbrutinib · TG-1701, SHR-1459

Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK)

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Edralbrutinib?

Edralbrutinib is an orally available small molecule that covalently and irreversibly binds Bruton's tyrosine kinase (BTK), blocking B-cell antigen receptor signaling and BTK-mediated survival pathways. It is being studied in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TG-1701, SHR-1459
Drug type
Small molecule
Targets
Bruton's tyrosine kinase (BTK)
Mechanism
Inhibitor of Bruton's tyrosine kinase (BTK)
Pathways
B-cell antigen receptor (BCR) signaling, BTK-mediated activation of downstream survival pathways
Therapy area
Oncology
In trials of
TGTX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
SG5I5QTR4E

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03671590 Phase 1 Non Hodgkin Lymphoma Terminated TGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Lymphocytic LeukemiaNon Hodgkin Lymphoma

Other drugs acting on BTK

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.